"Lactams" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.
| Descriptor ID |
D007769
|
| MeSH Number(s) |
D02.065.589 D03.383.411
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactams".
Below are MeSH descriptors whose meaning is more specific than "Lactams".
This graph shows the total number of publications written about "Lactams" by people in this website by year, and whether "Lactams" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lactams" by people in Profiles.
-
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Antiviral Res. 2024 07; 227:105920.
-
Emerging data in COVID-19 create urgent challengers for health providers: Updates on COVID-19 vaccine and Paxlovid. J Natl Med Assoc. 2024 Apr; 116(2 Pt 1):174-179.
-
Genetic determinants underlying the progressive phenotype of ?-lactam/?-lactamase inhibitor resistance in Escherichia coli. Microbiol Spectr. 2023 Dec 12; 11(6):e0222123.
-
Safely Prescribing Opioids With Nirmatrelvir/Ritonavir - Case Report and Management Recommendations. J Pain Symptom Manage. 2024 01; 67(1):e99-e104.
-
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023 Oct; 622(7982):376-382.
-
Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment. N Engl J Med. 2022 09 15; 387(11):1045-1047.
-
Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors. J Pediatr Hematol Oncol. 2021 07 01; 43(5):e718-e722.
-
Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
-
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clin Cancer Res. 2020 01 01; 26(1):242-255.
-
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun. 2017 12 22; 8(1):2270.